<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:04:23Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/16833" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/16833</identifier><datestamp>2026-10-18T20:38:56Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>A Comparison of Weekly DCF versus Standard DCF as First-line Systemic Chemotherapy for Metastatic Gastric Cancer Patients</dc:title><dc:creator>Aldemir, M. N.</dc:creator><dc:creator>Turkeli, M.</dc:creator><dc:creator>Simsek, M.</dc:creator><dc:creator>Yildirim, N.</dc:creator><dc:creator>Bilici, M.</dc:creator><dc:creator>Dogan, C.</dc:creator><dc:creator>Tekin, S. B.</dc:creator><dc:subject>Cisplatin</dc:subject><dc:subject>docetaxel</dc:subject><dc:subject>infusional 5-fluorouracil</dc:subject><dc:subject>metastatic gastric cancer</dc:subject><dc:subject>PLUS FLUOROURACIL</dc:subject><dc:subject>PHASE-III</dc:subject><dc:subject>TRIAL</dc:subject><dc:subject>5-FLUOROURACIL</dc:subject><dc:subject>EPIRUBICIN</dc:subject><dc:subject>THERAPY</dc:subject><dc:subject>Medicine, General &amp; Internal</dc:subject><dc:subject>General &amp; Internal Medicine</dc:subject><dc:description>Objective: In metastatic gastric cancer (MGC), the goals of treatment are palliation and prolongation of overall survival (OS). Systemic chemotherapy, with docetaxel, cisplatin, infusional 5-fluorouracil (DCF) the most preferred regimen, is the mainstay of the treatment. We evaluated the efficacy and tolerability of weekly DCF (wDCF) compared to standard DCF regimen. Methods: We retrospectively reviewed 49 and 32 MGC patients treated with DCF and wDCF regimens as first-line treatment, respectively. The wDCF protocol included 25 mg/m(2) docetaxel, 25 mg/m(2) cisplatin and 750 mg/m(2) infusional 5-FU on day 1, every week. Each cycle was repeated every 3 weeks. Results: The patients in wDCF arm were significantly older (median 54 vs 72.5) and had poor Eastern Cooperative Oncology Group performance status (ECOG PS) than patients in DCF arm (p &lt; 0.001). Progression-free survival was 3 vs 5 months (p=0.75) and OS was 7 vs 9 months in wDCF and DCF arms (p=0.33), respectively. Overall response rate was observed in 28.5 and 31.2% of the patients in DCF and wDCF arms, respectively (p = 0.65). Haematologic toxicities were observed more common in wDCF arm. Conclusion: Weekly DCF is an effective and tolerable regimen and may be an alternative in patients who are elderly and have poor ECOG PS.</dc:description><dc:publisher>UNIV WEST INDIES FACULTY MEDICAL SCIENCES</dc:publisher><dc:date>2023</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/16833</dc:identifier><dc:identifier>https://doi.org/10.7727/wimj.2016-536</dc:identifier><dc:identifier>0043-3144</dc:identifier><dc:language>en</dc:language><dc:relation>WEST INDIAN MEDICAL JOURNAL</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/16833</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>